ReviewCancers2022
Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Evaluation of surgical outcomes and prognostic factors of second primary lung cancer based on a systematic review and meta-analysis.BMC surgery · 2023Pooled it
- The impact of tislelizumab immunotherapy on multiple primary lung cancer presenting as ground-glass nodules: preliminary results analysis from a single-arm, phase II trial.Cancer immunology, immunotherapy : CII · 2025Trial
- Diagnosis and selection of surgical approaches for synchronous multiple primary lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- Incidence of Second Primaries and Recurrent Disease in Early-Stage Lung Cancer: What Can We Expect in a Nodule-Care Center Cohort?Respiration; international review of thoracic diseases · 2026Article
- Article
- Robotic-assisted and electromagnetic navigation bronchoscopy for multi-focal lung cancers: a narrative review.Translational lung cancer research · 2025Review
- Decoding the enigma of multiple primary lung cancers: from mechanism to bedside-a narrative review.Translational lung cancer research · 2025Review
- [Triple synchronous primary lung adenocarcinoma: A diagnostic challenge].Anales del sistema sanitario de Navarra · 2025Article
- Immune microenvironment heterogeneity of concurrent adenocarcinoma and squamous cell carcinoma in multiple primary lung cancers.NPJ precision oncology · 2024Article
- Long-term prognosis analysis of surgical therapy for bilateral synchronous multiple primary lung cancer: a follow-up of 293 cases.Journal of thoracic disease · 2024Article
- Genomic alterations in oral multiple primary cancers.International journal of oral science · 2024Article
- Diagnosis and management of multiple primary lung cancer.Frontiers in oncology · 2024Review
- Lobar or sublobar resection for early-stage second primary lung cancer ≤ 3 cm in size: a SEER population-based study.Journal of cancer research and clinical oncology · 2023Article
- Case report: Targeted sequencing facilitates the diagnosis and management of rare multifocal pure ground-glass opacities with intrapulmonary metastasis.Frontiers in oncology · 2023Article
- New method for discrimination of multiple primary lung cancer and metastatic lung cancer.Thoracic cancer · 2022Article
- Comprehensive analysis of DTYMK in pan-cancer and verification in lung adenocarcinoma.Bioscience reports · 2022Article
- Multiple primary lung cancer tumors with diversified genetic mutations-complications in choosing therapeutic options.Clinical and translational discovery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
With the wide application of computed tomography in lung cancer screening, the incidence of multiple primary lung cancer (MPLC) has been increasingly reported. Despite the established criteria, the differentiation between MPLC and intrapulmonary metastasis remains challenging. Although histologic features are helpful in some circumstances, a molecular analysis is often needed. The application of next-generation sequencing could aid in distinguishing MPLCs from intrapulmonary metastasis, decreasing ambiguity. For MPLC management, surgery with lobectomy is the main operation method. Limited resection does not appear to negatively affect survival, and it is a reasonable alternative. Stereotactic ablative radiotherapy (SABR) has become a standard of care for patients refusing surgery or for those with medically inoperable early-stage lung cancer. However, the efficacy of SABR in MPLC management could only be found in retrospective series. Other local ablation techniques are an emerging alternative for the control of residual lesions. Furthermore, systemic therapies, such as targeted therapy for oncogene-addicted patients, and immunotherapy have shown promising results in MPLC management after resection. In this paper, the recent advances in the diagnosis and management of MPLC are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.